apricus wealth LLC Has $410,000 Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

apricus wealth LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 37.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 824 shares of the medical research company’s stock after buying an additional 224 shares during the quarter. apricus wealth LLC’s holdings in Thermo Fisher Scientific were worth $410,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Cypress Advisory Group LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $253,000. Intact Investment Management Inc. grew its position in Thermo Fisher Scientific by 34.0% in the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company’s stock valued at $1,353,000 after purchasing an additional 660 shares during the period. Purkiss Capital Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $1,121,000. W.H. Cornerstone Investments Inc. grew its position in Thermo Fisher Scientific by 25.1% in the 4th quarter. W.H. Cornerstone Investments Inc. now owns 2,870 shares of the medical research company’s stock valued at $1,493,000 after purchasing an additional 576 shares during the period. Finally, Van ECK Associates Corp grew its position in Thermo Fisher Scientific by 19.7% in the 4th quarter. Van ECK Associates Corp now owns 418,365 shares of the medical research company’s stock valued at $217,646,000 after purchasing an additional 68,927 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.33% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts recently issued reports on TMO shares. Barclays reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Royal Bank of Canada reduced their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Scotiabank reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research report on Friday, April 25th. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, April 24th. Finally, The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 23rd. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $605.30.

Thermo Fisher Scientific Trading Up 0.2%

NYSE TMO opened at $415.25 on Thursday. The stock has a market capitalization of $156.76 billion, a price-to-earnings ratio of 25.12, a PEG ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The business’s fifty day moving average is $417.57 and its 200-day moving average is $493.84.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. During the same period in the previous year, the business posted $5.11 EPS. The business’s revenue for the quarter was up .2% compared to the same quarter last year. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.